Compare Lumen Technologies Inc (LUMN) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lumen Technologies Inc vs Pfizer Inc — how do they compare? Lumen Technologies Inc trades at $5.3 (market cap $5.73B), while Pfizer Inc trades at $28.18 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 27.7× Lumen Technologies Inc's market cap, and Pfizer Inc pays a 6.18% dividend while Lumen Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lumen Technologies Inc for 40 Days and Pfizer Inc for 158 Days on average.
| LUMN | PFE | |
|---|---|---|
Market Cap | $5.73B | $158.56B |
Volume | 17,079,799 | 44,138,282 |
Sector | Media | Health |
52-Week High | $11.83 | $29.02 |
52-Week Low | $5.53 | $23.67 |
Typical Hold Time | 40 Days | 158 Days |
Enterprise Value | $17.35B | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LUMN trades at $5.20, down 12.01% in 24 hours, reflecting bearish technical signals and negative profitability. Revenue declined to $12.40B in 2025 with a net loss of $1.74B, though recent product launches like Intelligent Internet target AI-driven growth. The stock faces high debt levels at $17.49B long-term, while analyst consensus is predominantly Hold (60.71%) with a Reduce rating average.
The outlook remains challenged by legacy revenue declines and substantial debt, but strategic pivots to AI networking offer speculative upside. Key risks include persistent losses and competitive pressures, requiring careful monitoring of cash flow and execution on new initiatives for any sustained recovery.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
